Peptides where the controlled human evidence is still emerging

Why this article exists

For most peptides discussed in user communities, the implicit framing is about what happens in humans — recovery, body composition, longevity, cognition. It's easy to assume that the volume of discussion tracks the volume of human evidence. For several of the most-discussed compounds, it doesn't.

This article walks through the specific compounds where that gap is largest, frames the gap honestly, and notes where the open research questions are. The point isn't to dismiss any of these compounds — most have biology worth taking seriously — but to calibrate what's actually been demonstrated in controlled human studies versus what's been inferred from animal data plus user reports.

BPC-157

The pentadecapeptide most discussed for tissue recovery. The animal-model literature is broad and consistent within its primary research lineage. Controlled human RCTs for tendon, ligament, or any other indication have not been published in mainstream clinical journals. See our dedicated read.

TB-500

A synthetic 17-amino-acid fragment of thymosin beta-4. Most published human evidence is for full-length thymosin beta-4 (in cardiac and ophthalmologic contexts), not the TB-500 fragment specifically. Users typically purchase TB-500, and the inference from full-length-TB-4 data is real but not equivalent to direct evidence for the marketed compound.

Injected GHK-Cu

GHK-Cu has substantial cosmetic and topical wound-healing evidence — that's well-established. Systemic / injectable GHK-Cu use has a much thinner human evidence base. Most injectable GHK-Cu claims are extrapolations from topical research, with mechanistic plausibility but limited direct controlled-trial support.

Epitalon

The Khavinson-group tetrapeptide with reported telomerase-related effects and multi-decade mortality follow-up data in elderly Russian cohorts. Independent replication outside Russia has been limited, and the proposed mechanisms remain controversial outside the originating research lineage. The findings would be extraordinary if independently confirmed; that confirmation has been elusive.

DSIP

Delta sleep-inducing peptide was discovered in rabbit brain in the 1970s. Most human evidence comes from small, often open-label studies; large modern RCTs are limited. Sleep-architecture claims are mechanistically plausible but the controlled-trial evidence base is thinner than the user-community framing suggests.

Selank and Semax

Russian synthetic heptapeptides with claims around anxiolysis (Selank) and cognitive support (Semax). Russian-language trial literature is more substantial than Western coverage acknowledges; English-language replication outside Russia has been limited. See our read on the Russian peptide tradition for context.

Humanin

Mitochondrial-derived peptide with fascinating preclinical findings in metabolic and neurological models. Human evidence for exogenous administration in any indication is essentially absent. The basic biology is real; clinical translation hasn't happened yet.

FOXO4-DRI

Senolytic D-retro-inverso peptide that captured significant attention with the 2017 Cell paper. Despite the initial prominence, formal human clinical development has been slower than the public visibility would suggest. See our read on senolytics for the broader field context.

SLU-PP-332 and other exercise mimetics

The most-discussed recent addition to the exercise-mimetic conversation. All available evidence is preclinical mouse data. See our read on the exercise-mimetic question for the translational context.

What this category isn't

Limited human evidence isn't the same as no evidence, isn't the same as no biology, and isn't the same as the compound not working. It means the controlled human-trial work hasn't been done at the scale the discussion volume implies. For someone making decisions, the practical question is: are you comfortable acting on the evidence base that exists, or do you want the evidence base that hasn't been built yet?